 Patients with histological proven advanced gastric cancer including cancer of the esophagogastric junction AEG without evidence of distant metastases, who fulfill the inclusion and exclusion criteria, can be recruited in this study. There are two treatment groups A and B. The D2 radical gastrectomy will be applied in both groups. Patients randomized into group B will be treated with an intraperitoneal in the abdominal cavity chemoperfusion with cisplatin75mgm2 max 150mgm2 max 5L . Patients randomized into group A will not accept intraperitoneal chemoperfusion. Patients in both groups receive 6 cycles of postoperative chemotherapy SOX or XELOX within 4-12 weeks after the surgical procedure and are followed up for 24 months. 